Andreas Halvorsen: portfolio of Viking Global Investors
Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.
Source: 13F filing with the US Securities and Exchange Commission dated Nov 14, 2022. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q3 2022. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 21.6B USD
- Positions
- 87
- Share of the ten largest
- 37.9%
The ten largest positions Q3 2022
- Elevance Health 4.9%▲ +59.6%
- Amazon 4.9%▲ +14.6%
- Visa Inc. 4.4%▲ +109.2%
- McKesson Corporation 4.1%▲ +60.5%
- Microsoft 3.8%▲ +18.5%
- GE Aerospace 3.7%▲ +47.1%
- Meta Platforms 3.4%▲ +86.7%
- Chubb Limited 3.0%▼ −4.8%
- Boston Scientific 2.9%▲ +10.3%
- Brookfield Asset Mgmt Inc 2.8%▲ +21.6%
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q3 2022
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| ELV Elevance Health | 4.9% | 2,336,841 | 1.1B USD | +59.6% increased | Q1 2022 3 quarters |
| AMZN Amazon | 4.9% | 9,286,956 | 1.0B USD | +14.6% increased | Q2 2015 30 quarters |
| V Visa Inc. | 4.4% | 5,346,584 | 949.8M USD | +109.2% increased | Q3 2016 25 quarters |
| MCK McKesson Corporation | 4.1% | 2,608,580 | 886.6M USD | +60.5% increased | Q2 2022 2 quarters |
| MSFT Microsoft | 3.8% | 3,510,344 | 817.6M USD | +18.5% increased | Q2 2016 26 quarters |
| GE GE Aerospace | 3.7% | 12,874,144 | 797.0M USD | +47.1% increased | Q4 2020 8 quarters |
| META Meta Platforms | 3.4% | 5,351,499 | 726.1M USD | +86.7% increased | Q4 2020 8 quarters |
| CB Chubb Limited | 3.0% | 3,593,242 | 653.5M USD | −4.8% reduced | Q1 2020 11 quarters |
| BSX Boston Scientific | 2.9% | 16,162,921 | 626.0M USD | +10.3% increased | Q3 2018 17 quarters |
| Brookfield Asset Mgmt Inc | 2.8% | 14,757,027 | 603.4M USD | +21.6% increased | Q2 2021 6 quarters |
| DG Dollar General | 2.7% | 2,426,368 | 582.0M USD | +118.6% increased | Q1 2022 3 quarters |
| Hdfc Bank Ltd | 2.6% | 9,713,845 | 567.5M USD | +5.8% increased | Q3 2021 5 quarters |
| MA Mastercard | 2.3% | 1,770,583 | 503.4M USD | −23.1% reduced | Q1 2022 3 quarters |
| AMP Ameriprise Financial | 2.1% | 1,803,989 | 454.5M USD | +52.4% increased | Q1 2021 7 quarters |
| Api Group Corp | 2.1% | 33,819,567 | 448.8M USD | +0.5% increased | Q2 2020 10 quarters |
| INTU Intuit | 2.1% | 1,157,479 | 448.3M USD | +3.8% increased | Q2 2022 2 quarters |
| TMUS T-Mobile US | 2.1% | 3,324,606 | 446.1M USD | −63.7% reduced | Q1 2020 11 quarters |
| Royalty Pharma PLC | 2.0% | 10,881,594 | 437.2M USD | −12.0% reduced | Q2 2020 10 quarters |
| UBER Uber | 2.0% | 16,396,107 | 434.5M USD | −1.1% reduced | Q3 2021 5 quarters |
| Biomarin Pharmaceutical Inc | 2.0% | 5,099,164 | 432.3M USD | +0.9% increased | Q4 2021 4 quarters |
| PH Parker Hannifin | 2.0% | 1,775,453 | 430.2M USD | −42.2% reduced | Q2 2020 10 quarters |
| FTV Fortive | 1.6% | 6,076,200 | 354.2M USD | −48.5% reduced | Q3 2019 13 quarters |
| CRM Salesforce | 1.6% | 2,400,649 | 345.3M USD | new | Q3 2022 1 quarter |
| IFF International Flavors & Fragrances | 1.6% | 3,726,736 | 338.5M USD | −27.2% reduced | Q4 2021 4 quarters |
| Ginkgo Bioworks Holdings Inc | 1.5% | 101,834,126 | 317.7M USD | +276.0% increased | Q3 2021 5 quarters |
| TTWO Take-Two Interactive | 1.4% | 2,804,400 | 305.7M USD | +40.2% increased | Q4 2021 4 quarters |
| TMO Thermo Fisher Scientific | 1.4% | 593,537 | 301.0M USD | −31.2% reduced | Q2 2020 10 quarters |
| XYZ Block, Inc. | 1.4% | 5,311,049 | 292.1M USD | −5.2% reduced | Q4 2021 4 quarters |
| Roivant Sciences Ltd | 1.3% | 88,238,700 | 284.1M USD | unchanged | Q4 2021 4 quarters |
| MU Micron Technology | 1.3% | 5,413,915 | 271.2M USD | +268.1% increased | Q2 2022 2 quarters |
| Bridgebio Pharma Inc | 1.2% | 26,620,991 | 264.6M USD | unchanged | Q2 2019 14 quarters |
| WDC Western Digital | 1.1% | 7,400,746 | 240.9M USD | +276.4% increased | Q2 2022 2 quarters |
| Acadia Healthcare Company In | 1.1% | 2,958,932 | 231.3M USD | −14.9% reduced | Q4 2020 8 quarters |
| Karuna Therapeutics Inc | 1.1% | 1,014,116 | 228.1M USD | −9.4% reduced | Q3 2020 9 quarters |
| Adaptive Biotechnologies Cor | 1.0% | 29,993,708 | 213.6M USD | unchanged | Q2 2019 14 quarters |
| Guardant Health Inc | 1.0% | 3,835,610 | 206.5M USD | −14.4% reduced | Q3 2019 13 quarters |
| Unum Group | 0.9% | 5,074,658 | 196.9M USD | +17.7% increased | Q1 2022 3 quarters |
| UNH UnitedHealth Group | 0.8% | 348,550 | 176.0M USD | new | Q3 2022 1 quarter |
| Amylyx Pharmaceuticals Inc | 0.8% | 5,770,536 | 162.4M USD | −19.5% reduced | Q1 2022 3 quarters |
| MRSH Marsh McLennan | 0.7% | 1,006,898 | 150.3M USD | −64.4% reduced | Q4 2020 8 quarters |
| Valvoline Inc | 0.7% | 5,847,839 | 148.2M USD | new | Q3 2022 1 quarter |
| PYPL PayPal | 0.7% | 1,713,801 | 147.5M USD | new | Q3 2022 1 quarter |
| CME CME Group | 0.7% | 831,110 | 147.2M USD | +63.4% increased | Q2 2022 2 quarters |
| PODD Insulet Corporation | 0.6% | 611,038 | 140.2M USD | +21.4% increased | Q3 2020 9 quarters |
| KKR KKR & Co. | 0.6% | 3,177,089 | 136.6M USD | new | Q3 2022 1 quarter |
| Molina Healthcare Inc | 0.6% | 406,671 | 134.1M USD | −14.4% reduced | Q3 2019 13 quarters |
| SE Sea Limited (ADR) | 0.6% | 2,362,871 | 132.4M USD | new | Q3 2022 1 quarter |
| Rogers Comms B | 0.6% | 3,378,977 | 130.2M USD | new | Q3 2022 1 quarter |
| CRL Charles River Laboratories | 0.6% | 658,478 | 129.6M USD | +19.0% increased | Q1 2021 7 quarters |
| NOW ServiceNow | 0.6% | 323,368 | 122.1M USD | +8.7% increased | Q4 2020 8 quarters |
| Catalent Inc | 0.6% | 1,673,755 | 121.1M USD | −14.7% reduced | Q1 2018 19 quarters |
| Inspire Med Sys Inc | 0.5% | 633,572 | 112.4M USD | +6.4% increased | Q1 2022 3 quarters |
| Intellia Therapeutics Inc | 0.5% | 1,889,067 | 105.7M USD | −15.2% reduced | Q2 2021 6 quarters |
| Zoominfo Technologies Inc | 0.5% | 2,512,177 | 104.7M USD | new | Q3 2022 1 quarter |
| Rh | 0.5% | 414,729 | 102.1M USD | +3.4% increased | Q2 2022 2 quarters |
| BABA Alibaba Group (ADR) | 0.5% | 1,246,400 | 99.7M USD | new | Q3 2022 1 quarter |
| CDNS Cadence Design Systems | 0.5% | 605,539 | 99.0M USD | new | Q3 2022 1 quarter |
| Inhibrx Inc | 0.4% | 5,305,866 | 95.2M USD | unchanged | Q3 2020 9 quarters |
| Zai Lab Ltd | 0.4% | 2,614,817 | 89.4M USD | −20.8% reduced | Q1 2021 7 quarters |
| PGR Progressive Corporation | 0.4% | 736,561 | 85.6M USD | −18.3% reduced | Q1 2022 3 quarters |
| LIN Linde plc | 0.4% | 311,600 | 84.0M USD | new | Q3 2022 1 quarter |
| CLX Clorox | 0.4% | 606,655 | 77.9M USD | new | Q3 2022 1 quarter |
| BEKE KE Holdings | 0.3% | 3,895,000 | 68.2M USD | −62.6% reduced | Q4 2021 4 quarters |
| Apellis Pharmaceuticals Inc | 0.3% | 932,441 | 63.7M USD | new | Q3 2022 1 quarter |
| Rallybio Corp | 0.3% | 4,194,777 | 60.7M USD | unchanged | Q3 2021 5 quarters |
| Avantor Inc | 0.3% | 2,898,662 | 56.8M USD | −53.0% reduced | Q2 2019 14 quarters |
| RIVN Rivian Automotive | 0.2% | 1,602,193 | 52.7M USD | unchanged | Q4 2021 4 quarters |
| CRWD CrowdStrike | 0.2% | 284,329 | 46.9M USD | new | Q3 2022 1 quarter |
| Shockwave Med Inc | 0.2% | 157,327 | 43.7M USD | −44.6% reduced | Q2 2022 2 quarters |
| Edgewise Therapeutics Inc | 0.2% | 4,409,146 | 43.4M USD | +61.7% increased | Q1 2021 7 quarters |
| Global E Online Ltd | 0.2% | 1,575,580 | 42.2M USD | −48.3% reduced | Q4 2021 4 quarters |
| Orion Acquisition Corp | 0.2% | 3,629,247 | 35.8M USD | −2.0% reduced | Q1 2021 7 quarters |
| 4D Molecular Therapeutics In | 0.1% | 3,937,914 | 31.7M USD | unchanged | Q4 2020 8 quarters |
| Day One Biopharmaceuticals I | 0.1% | 1,558,563 | 31.2M USD | −16.1% reduced | Q2 2021 6 quarters |
| CBRE CBRE Group | 0.1% | 409,714 | 27.7M USD | new | Q3 2022 1 quarter |
| DPZ Domino's | 0.1% | 74,968 | 23.3M USD | new | Q3 2022 1 quarter |
| Kinnate Biopharma Inc | 0.1% | 1,820,462 | 21.8M USD | unchanged | Q4 2020 8 quarters |
| Upstart HLDGS Inc | < 0.1% | 999,647 | 20.8M USD | new | Q3 2022 1 quarter |
| Pharvaris N V | < 0.1% | 2,496,923 | 20.1M USD | +0.2% increased | Q1 2021 7 quarters |
| Tenet Healthcare Corp | < 0.1% | 383,510 | 19.8M USD | new | Q3 2022 1 quarter |
| Match Group Inc New | < 0.1% | 381,750 | 18.2M USD | new | Q3 2022 1 quarter |
| Pepgen Inc | < 0.1% | 1,793,923 | 16.3M USD | unchanged | Q2 2022 2 quarters |
| LVS Las Vegas Sands | < 0.1% | 379,551 | 14.2M USD | −60.7% reduced | Q2 2022 2 quarters |
| Talaris Therapeutics Inc | < 0.1% | 3,289,617 | 8.7M USD | unchanged | Q2 2021 6 quarters |
| Verastem Inc | < 0.1% | 9,224,000 | 7.8M USD | unchanged | Q2 2022 2 quarters |
| Lianbio | < 0.1% | 3,564,173 | 7.1M USD | unchanged | Q4 2021 4 quarters |
| Trevi Therapeutics Inc | < 0.1% | 4,400,000 | 6.8M USD | new | Q3 2022 1 quarter |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Plus 1 position in convertible bonds and bonds worth 87.9M USD as reported – not included in the weights.
Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.
- Guardant Health Inc principal 120.0M USD 87.9M USD
Breakdown by sector
- Financials 16.3%
- Health Care 15.4%
- Technology 11.1%
- Industrials 9.3%
- Communication Services 6.9%
- Consumer Discretionary 5.3%
- Consumer Staples 3.1%
- Materials 2.0%
- Real Estate 0.1%
- not in our coverage 30.6%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors